title: [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
abstract: A comparative analysis of efficacy and tolerability of such immunomodulating compounds as rebif 22-mcg and copaxone used in the treatment of multiple sclerosis is presented. The analysis was based on the data obtained in the 2-year study of copaxone (145 patients) and rebif 22-mcg (74 patients) therapy carried out in the Neurology Institute, Russian Academy of Medical Sciences.
authors.forename: I A
authors.initials: IA
authors.lastname: Zavalishin
authors.forename: A V
authors.initials: AV
authors.lastname: Peresedova
authors.forename: N I
authors.initials: NI
authors.lastname: Stoĭda
authors.forename: O iu
authors.initials: Oi
authors.lastname: Rebrova
authors.forename: M N
authors.initials: MN
authors.lastname: Zakharova
authors.forename: L S
authors.initials: LS
authors.lastname: Adarcheva
authors.forename: A S
authors.initials: AS
authors.lastname: Niazbekova
authors.forename: L Sh
authors.initials: LSh
authors.lastname: Askarova
authors.forename: E V
authors.initials: EV
authors.lastname: Baĭdina
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a